Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib for CRS Prevention in Older Patients Undergoing PBSCT
NCT05823571Phase 1Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacitinib in cytokine release syndrome (CRS) and graft-versus-host disease (GVHD), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of participant deaths at 14 days, Number of participants with grade 3 or higher CRS at 14 days and 2 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
itacitinib
03
Conditions
cytokine release syndrome (CRS)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05823571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823571.